月经后应用右归丸加减治疗肾阳虚型月经性偏头痛的临床研究OA

Objective To investigate the clinical efficacy and mechanism of modified Yougui Pills in treating menstrual migraine with kidney-yang deficiency syndrome during the postmenstrual phase.Methods Medical records of 100 patients with menstrual migraine of kidney-yang deficiency syndrome from the Neurology Department of Shenzhen Bao'an Traditional Chinese Medicine Hospital between February 2024 and February 2025 were retrospectively screened,and the patients were divided into an exposure group and a control group(n=50 each)based on actual treatment.The exposure group received modified Yougui Pills combined with flunarizine hydrochloride,while the control group received flunarizine hydrochloride alone.Both groups were treated for three consecutive courses,with for one menstrual cycle as one course.Migraine scores,Headache Impact Test-6(HIT-6)scores,and serum levels of estradiol(E2)and serotonin(5-HT)were observed before treatment and after three treatment courses.Clinical efficacy and medication safety were evaluated.Results(1)Regarding efficacy,after three treatment courses,the total effective rate was 90.0%(45/50)in the exposure group versus 76.0%(38/50)in the control group.Intergroup comparison(by chi-square test)showed significantly superior clinical efficacy in the exposure group(P＜0.05).(2)Regarding migraine scores,after three treatment courses,migraine scores significantly decreased in both groups compared to those before treatment(P＜0.05),with a significantly greater reduction in the exposure group(P＜0.05).(3)Regarding impact on life,after three treatment courses,HIT-6 scores significantly decreased in both groups compared to those before treatment(P＜0.05),with a significantly greater reduction in the exposure group(P＜0.05).(4)Regarding serology,after three treatment courses,serum E2 and 5-HT levels significantly increased in both groups compared to before treatment(P＜0.05),with significantly greater increases in the exposure group(P＜0.05).(5)Regarding safety,no severe adverse reactions occurred in either group during treatment.Most adverse reactions were mild,such as drowsiness,fatigue,and low mood.The incidence of adverse reactions was 4.0%(2/50)in the control group and 2.0%(1/50)in the exposure group,with no statistically significant difference between groups(P＞0.05).All adverse reactions were mild and required no special intervention.Conclusion Modified Yougui Pills administered during the postmenstrual phase for menstrual migraine with kidney-yang deficiency syndrome significantly improve clinical efficacy,reduce the severity attack frequency,and duration of migraine,alleviate migraine symptoms,and promote patient recovery with a favorable safety profile.